Our Founders

Genomic Health's Scientific Founders

In 2000, inspired by a close friend’s cancer diagnosis, Randy Scott founded Genomic Health in Redwood City, California with the goal of developing high-value diagnostics to enable more personalized cancer treatment decisions based on the genomic activity within a patient’s individual tumor.


Randy Scott, Ph.D.

Randy ScottRandy Scott is co-founder, chairman and CEO of Invitae Corporation (NYSE: NVTA), a company focused on bringing comprehensive genetic information into routine medical practice to improve the quality of healthcare for billions of people by making genetic testing more affordable and accessible. Prior to starting Invitae, Dr. Scott founded Genomic Health (NASDAQ: GHDX) in 2000 and led the company as CEO for nine years with a focus on improving the quality of treatment decisions for patients with cancer. Dr. Scott has played a role in founding several successful biotech companies in addition to Genomic Health Inc., including Incyte (NASDAQ: INCY), a genomic information company. Dr. Scott, an author of more than 40 scientific publications, 20 patents, and recipient of numerous awards, holds a Bachelor of Science degree in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas.


Genomic Health Founder Randy Scott talks about the company's ahead-of-its-time vision and the many doubters that tried to derail what Genomic Health set out to do from Day 1, and has since been very success at.


Steven Shak, M.D.

Dedicated to optimizing cancer treatment outcomes and bringing the patient voice into product development, Steve Shak, M.D. has served as Co-Founder, Chief Scientific Officer since 2012 and was Chief Medical Officer from 2000 to 2013. Under Steve's leadership Genomic Health used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype DX breast cancer and colon cancer assays and has maintained an 80% product development success rate. Steve has been a leader in personalized medicine for more than two decades. Prior to co-founding Genomic Health in 2000, Steve served for 14 years in various roles in discovery research and medical affairs at Genentech, Inc., a biotechnology company dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Steve led the clinical team that gained approval for Herceptin®, a targeted biologic treatment for breast cancer. He also initiated the cancer clinical trials of the anti-angiogenesis agent, Avastin®. In addition, Steve discovered Pulmozyme®, a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease cystic fibrosis. Prior to joining Genentech, Steve was an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. Steve holds a Bachelor of Arts degree in Chemistry from Amherst College and an M.D. degree from New York University School of Medicine, and completed his post-doctoral training at the University of California, San Francisco.


Breast cancer patients can easily receive the Oncotype DX Breast Cancer Assay, according to Dr. Steven Shak of Genomic Health.


Joffre Baker, Ph.D.

Since co-founding the company in 2000, Joffre Baker, Ph.D. has served as Co-Founder, Senior Biology Fellow and has overseen the research and development teams behind the breast, colon and prostate cancer programs at Genomic Health. Joffre and his team are currently deploying Next Generation Sequencing technology and its application across all research initiatives in an effort to connect either gene mutations or expression profiles to clinical outcomes and provide additional personalized information to physicians and patients beyond that already available through the use of Oncotype DX. Prior to cofounding Genomic Health in 2000, Joffre served as Vice President for Research Discovery at Genentech, Inc., a biotechnology company, dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. From 1993 to 2000, Joffre oversaw Research Discovery at Genentech, which included the Departments of Cardiovascular Research, Oncology, Immunology, Endocrinology and Pathology. From 1991 to 1993, he served as Genentech’s Director of Cardiovascular Research. Prior to joining Genentech, Joffre was a faculty member in the Department of Biochemistry at the University of Kansas. He holds a Bachelor of Science degree in Biology and Chemistry from the University of California, San Diego and a Ph.D. in Biochemistry from the University of Hawaii. Joffre is the recipient of a NIH (National Institutes of Health) Research Career Development Award (1983 – 1988), and is the author of over 65 publications.

Learn more about Genomic Health

Oncotype DX My Colon Cancer Coach